enGene Holdings Inc. (NASDAQ:ENGN) Receives Consensus Recommendation of "Buy" from Brokerages

enGene Holdings Inc. (NASDAQ:ENGN - Get Free Report) has earned an average recommendation of "Buy" from the eight research firms that are covering the company, MarketBeat reports. One research analyst has rated the stock with a hold recommendation, six have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $23.29.

Separately, JMP Securities restated a "market outperform" rating and issued a $18.00 target price on shares of enGene in a report on Tuesday, April 29th.

enGene Stock Performance

ENGN stock traded up $0.01 during mid-day trading on Friday, reaching $3.86. 47,024 shares of the stock traded hands, compared to its average volume of 122,504. The stock's fifty day moving average is $3.60 and its 200-day moving average is $4.83. The company has a debt-to-equity ratio of 0.09, a current ratio of 12.66 and a quick ratio of 12.66. enGene has a 52-week low of $2.65 and a 52-week high of $11.00.

enGene (NASDAQ:ENGN - Get Free Report) last posted its quarterly earnings results on Tuesday, June 10th. The company reported ($0.51) earnings per share for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.03). On average, research analysts expect that enGene will post -1.56 earnings per share for the current year.

Hedge Funds Weigh In On enGene

A number of hedge funds have recently made changes to their positions in ENGN. Jane Street Group LLC purchased a new position in enGene in the fourth quarter valued at $93,000. Toronto Dominion Bank purchased a new stake in shares of enGene in the 4th quarter valued at about $97,000. Cubist Systematic Strategies LLC increased its position in enGene by 15.7% in the 4th quarter. Cubist Systematic Strategies LLC now owns 15,342 shares of the company's stock valued at $102,000 after acquiring an additional 2,080 shares during the period. ADAR1 Capital Management LLC acquired a new position in enGene in the 1st quarter valued at about $107,000. Finally, Corton Capital Inc. acquired a new position in enGene in the 4th quarter valued at about $157,000. Institutional investors and hedge funds own 64.16% of the company's stock.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.